These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24165977)

  • 21. StatBite. FDA-required postmarketing studies, 1992-2008.
    J Natl Cancer Inst; 2010 Sep; 102(17):1303. PubMed ID: 20739654
    [No Abstract]   [Full Text] [Related]  

  • 22. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2002 Jun; 11(4):335-40; discussion 341-2. PubMed ID: 12138603
    [No Abstract]   [Full Text] [Related]  

  • 24. Painful lessons.
    Nat Rev Drug Discov; 2005 Oct; 4(10):800-3. PubMed ID: 16237842
    [No Abstract]   [Full Text] [Related]  

  • 25. Post-approval adverse events of new and old anticoagulants.
    Hoffman KB; Demakas A; Erdman CB; Dimbil M
    BMJ; 2014 Mar; 348():g1859. PubMed ID: 24603571
    [No Abstract]   [Full Text] [Related]  

  • 26. [Benefits and harms - two sides of the same medal?].
    Koch A
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(3):163-70. PubMed ID: 21530904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 28. Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.
    Chambers JD; Thorat T; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2017 Aug; 36(8):1408-1415. PubMed ID: 28784733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian statistics in medical devices: innovation sparked by the FDA.
    Campbell G
    J Biopharm Stat; 2011 Sep; 21(5):871-87. PubMed ID: 21830920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Withdrawing FDA approval of midodrine after marketing.
    Holtzman NA; Starfield B
    JAMA; 2011 Feb; 305(8):781-2; author reply 782. PubMed ID: 21343575
    [No Abstract]   [Full Text] [Related]  

  • 31. Oncology's trials.
    Booth B; Glassman R; Ma P
    Nat Rev Drug Discov; 2003 Aug; 2(8):609-10. PubMed ID: 12908467
    [No Abstract]   [Full Text] [Related]  

  • 32. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

  • 33. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 34. Ketek--the FDA perspective.
    Soreth J; Cox E; Kweder S; Jenkins J; Galson S
    N Engl J Med; 2007 Apr; 356(16):1675-6. PubMed ID: 17442912
    [No Abstract]   [Full Text] [Related]  

  • 35. Approval times and the safety of new pharmaceuticals.
    Rudholm N
    Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug provision of the Russian Federation's population and optimal measures for its improvement].
    Starodubov VI
    Vestn Ross Akad Med Nauk; 1999; (7):3-8. PubMed ID: 10467876
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 38. Re-examining our approach to the approval and use of new drugs.
    Lee SK
    CMAJ; 2006 Jun; 174(13):1855. PubMed ID: 16785460
    [No Abstract]   [Full Text] [Related]  

  • 39. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 40. US new drug applications increasingly rely on trials conducted abroad.
    Tanne JH
    BMJ; 2010 Jul; 341():c3616. PubMed ID: 20605887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.